Phase 3 N=9 Buprenorphine Treatment for Opioid Dependence
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Phase 2 N=10 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal Abstinence Syndrome · Neonatal Opiate Withdrawal Syndrome
Primary: Buprenorphine Pharmacokinetics
Phase 4 N=15 Buprenorphine Loading in the Emergency Department
Opioid-use Disorder
Primary: Number of Participants With Successful Rapid Induction — 14 Participants
Phase 2 N=12 Buprenorphine's Dose Response Curve
Opioid-related Disorders
Primary: Peak Change From Baseline in Drug Effect Assessed by Visual Analog Scale (VAS) — 17.75; 27.25; 29.63; 58.25 units on a scale
Phase 1 N=40 Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions
Healthy
Primary: Cmax of Buprenorphine. — 4.40; 3.88 ng/mL
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
Phase 3 N=147 SSRI and Buprenorphine
Opiate Dependence · Depression
Primary: Percentage of Participants Who Dropped Out of Buprenorphine Treatment — 33.3; 44.0 percentage of participants — p=.19
Phase 3 N=213 Buprenorphine for Prisoners
Heroin Addiction
Primary: Number of Days of Heroin Use — 6.0; 6.4; 6.5; 4.0 days
Phase 3 N=63 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Treatment — 15; 28 days — p=<0.05
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 4 N=54 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Opiate Addiction
Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77
Phase 4 N=785 Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
Moderate to Severe Opioid-use Disorder
Primary: Maintenance Phase: Percentage of Responders for Weekly Opioid Use Over Weeks 20 to 38 — 44; 50 Participants — p=0.4819
Phase 3 N=20 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
Opioid-Related Disorders · Heroin Dependence
Primary: The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit. — 6; 6 participants
Early Phase 1 N=48 The Effects of Buprenorphine on Responses to Verbal Tasks
Basic Science
Primary: Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Subjective Responses to…
N/A N=38 Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology
Depression
Primary: Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Subjective Response With…
Phase 3 N=17 Abuse Liability of Suboxone Versus Subutex
Opioid-related Disorders
Primary: Drug's Breakpoint — 1200; 10; 1100; 1200 number of clicks on a mouse
Phase 3 N=13 Buprenorphine for Treatment Resistant Depression
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Montgomery Asberg Depression Rating Scale — 33.8; 32.6 units on a scale
Phase 3 N=27 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
Heroin Dependence
Primary: Drug Self-administration — 350; 255; 223; 113 Clicks on a computer mouse
Phase 2 N=18 Buprenorphine Used With Treatment Resistant Depression in Older Adults
Major Depressive Disorder · Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — -1; -5.3; 21.3; 15.3 units on a scale
Phase 2 N=382 Safety and Tolerability of Buprenorphine/Naloxone Film Strips
Opioid-Related Disorders
Primary: Number of Subjects With Treatment-emergent Adverse Events Associated With the Oral Cavity. — 11; 16 Participants
Phase 4 N=281 Buprenorphine to Improve HIV Care Engagement and Outcomes
HIV · Substance Related Disorders
Primary: Number of Participants With HIV Viral Suppression — 97; 92; 74; 99 Participants
Phase 3 N=87 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
Opioid Dependence
Primary: Change of Opioid Use From Week 1 to 13 — 0.00; 0.27; 0.39 Mean Proportion of Opioid Use in Week 13 — p==0.00874
Phase 4 N=60 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
Opiate-related Disorders · Opiate Dependence · Drug Abuse
Primary: Subject's Self Assessment Using 10 cm Visual Analogue Scale (VAS) of Overall Preference for One of the Two Buprenorphine-based Maintenance Therapies (Suboxone® or…
Early Phase 1 N=71 Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075
Opioid Use Disorder
Primary: Recruitment Rate — 76; NA; NA; 71 Participants
Phase 2 N=100 Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
Pain, Postoperative
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 33; 47 Participants
Phase 3 N=302 Cocaine Use Reduction With Buprenorphine
Cocaine Dependence
Primary: Cocaine Use Days as Measured by Self-report, Corroborated by Thrice-weekly Urine Drug Screens — 6.6; 7.2; 7.7 days of cocaine use
Phase 3 N=758 Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
Opioid Dependence, on Agonist Therapy
Primary: Primary Endpoints of Retention in Treatment at Days 3 and 15 — 309; 302; 273; 269 participants
N/A N=12 Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
HIV Infections
Primary: Area Under the Curve of BUP/NLX With TPV/r (h*ng/mL) — 43.7 h*ng/mL
Phase 2 N=6 Nalrexone Facilitated Discontinuation of Buprenorphine
Stable Opioid Dependence
Primary: Successful Discontinuation of Buprenorphine — 6 Participants